NOVARTIS GRIMSBY LIMITED
Company Information
- Company Number
- 00170180
- Registered Address
- 2nd Floor, The Westworks Building White City Place, 195 Wood Lane, London, United Kingdom, W12 7FQ
- Status
- Active
- Employee Count
- 202
- Turnover
- Coming Soon
- EBITDA
- -£33,000
Additional Details
- Website
- https://novartis.co.uk
- Company Type
- Private limited Company
- Incorporated On
- 11 September 1920
- Nature of Business
- 20120 - Manufacture of dyes and pigments20130 - Manufacture of other inorganic basic chemicals20160 - Manufacture of plastics in primary forms21100 - Manufacture of basic pharmaceutical products
- Industries
- Raw Materials And Intermediate Goods
- Region
- London
Time to Pay
Payment Timeline
Payment Features
Payment Score History
Performance Reports History
| Reporting Period | Filing Date | Average Time to Pay (days) | Paid within 30 days | Paid 31-60 days | Paid after 60 days | Not Paid within Terms |
|---|---|---|---|---|---|---|
| 01 Jan 2024 - 30 Jun 2024 | 22 Jul 2024 | 52 | 11% | 46% | 43% | 31% |
| 01 Jul 2023 - 31 Dec 2023 | 17 Jan 2024 | 56 | 14% | 41% | 45% | 19% |
| 01 Jan 2022 - 30 Jun 2022 | 20 Jul 2022 | 50 | 10% | 63% | 27% | 10% |
| 01 Jul 2021 - 31 Dec 2021 | 25 Jan 2022 | 55 | 6% | 61% | 33% | 8% |
| 01 Jan 2021 - 30 Jun 2021 | 15 Jul 2021 | 54 | 11% | 52% | 37% | 16% |
| 01 Jan 2020 - 30 Jun 2020 | 29 Jul 2020 | 56 | 7% | 53% | 40% | 15% |
| 01 Jul 2018 - 31 Dec 2018 | 28 Jan 2019 | 48 | 19% | 54% | 27% | 19% |
| 01 Jan 2018 - 30 Jun 2018 | 27 Jul 2018 | 61 | 7% | 56% | 37% | 33% |
Payment Time Trends
Payment Distribution Trends
Invoice Payment Practices
This information is as reported by the business, and responses are in their own words.
Payment Terms
Standard payment terms
Standard payment terms are 60 days following the invoice receipt at Novartis. Depending on the commercial situation, variations to these standard terms might be negotiated on some occasions.
Were there any changes to the standard payment terms in the reporting period?
No information available
Any other information about payment terms
No additional information
Maximum contractual payment period agreed
90
Dispute Resolution Process
First point of contact for disputes or concerns is the Procure-to-Payment team within the Novartis Global Services Centre, for which all suppliers have contact details of. In addition to that, new suppliers receive an on-boarding pack, which includes information on issue raising and related points of contact. When an invoice dispute is received, it should be resolved at point of contact with the Procure-to-Payment team. If this is not possible, the query will be escalated to the Business contact and relevant senior Finance contact or P2P Business Partner. Timelines of escalation vary, depending on the nature of the query. When resolved, the invoice will be available for payment on the next standard payment run.
Other Payment Information
Has this business signed up to a code of conduct or standards on payment practices?
For example, signatories to The Prompt Payment Code must commit to paying 95% of their invoices within 60 days.
❌
Does this business offer e-invoicing in relation to qualifying contracts?
This is where suppliers can electronically submit and track invoices. It's not just allowing suppliers to email them an invoice.
❌
Does this business offer supply chain finance?
This is where a supplier who has submitted an invoice can be paid by a third-party finance provider earlier than the agreed payment date. The business would then pay the finance provider the invoiced sum.
❌
Under its payment practices and policies, can this business deduct sums from payments under qualifying contracts as a charge for remaining on a supplier list?
❌
During the reporting period, did the business deduct sums from payments as a charge for remaining on a supplier list?
No information available
Company Summary
NOVARTIS GRIMSBY LIMITED is a pharmaceutical company located in Grimsby, United Kingdom. The company is a subsidiary of the multinational healthcare company, Novartis AG, and was established in 1954. It is a leading producer of medicines and healthcare products, with a strong focus on sustainability.
The company's sustainability program is based on three pillars - environmental stewardship, access to healthcare, and ethical business practices. They aim to reduce their environmental impact by implementing sustainable practices in their operations, such as reducing energy consumption and using renewable energy sources. They also strive to increase access to healthcare by providing affordable and innovative medicines to patients in need, particularly in developing countries. Furthermore, they promote ethical business practices by ensuring transparency, integrity, and compliance in all their operations.
NOVARTIS GRIMSBY LIMITED offers a wide range of products and services, including prescription medicines, over-the-counter products, and generic drugs. They specialize in the production of respiratory, cardiovascular, and oncology medicines, as well as vaccines and eye care products. They also offer services such as disease management and health education programs.
The key people at NOVARTIS GRIMSBY LIMITED include Mr. Andrew Mitchell, the Managing Director, and Mr. Stephen Moran, the Director of Human Resources. They lead a team of dedicated professionals who are committed to the company's mission and values.
For any inquiries or information, the company can be contacted through their website, www.novartis.co.uk, or at their registered office address: Novartis Grimsby Limited, Pyewipe Road, Grimsby, North East Lincolnshire, DN31 2SP, United Kingdom.
In conclusion, NOVARTIS GRIMSBY LIMITED is a reputable pharmaceutical company with a strong commitment to sustainability, providing quality products and services globally. Their dedication to environmental responsibility, access to healthcare, and ethical business practices sets them apart in the industry.
